|Bid||138.73 x 100|
|Ask||138.84 x 100|
|Day's Range||138.41 - 141.32|
|52 Week Range||92.35 - 143.22|
|PE Ratio (TTM)||51.29|
|Earnings Date||Apr 23, 2018 - Apr 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||145.00|
IRVINE, Calif., March 19, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the U.S. Food and Drug Administration granted the De Novo request for Edwards' Acumen Hypotension Prediction Index (HPI) software. The company will initiate a targeted launch of this first-of-its-kind technology that leverages predictive analytics to alert clinicians to address potential hypotension, or low blood pressure, before it occurs in their surgical patients. "Even brief periods of hypotension are associated with complications or, worse, death after surgery," said Maxime Cannesson, MD, PhD, Professor and Vice Chair, Department of Anesthesiology and Perioperative Medicine, at UCLA.
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
The outlook for the US medical products and devices industry has been revised upward, to positive from stable, Moody's Investors Service says in a just-published report. Continued product innovation and ...
On March 6, 2018, Abbott Laboratories (ABT) announced that it received FDA (US Food and Drug Administration) approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants. The trial included patients five years and under who had damaged, diseased, or malfunctioning heart valves. On March 6, 2018, ABT stock rose ~0.86%, whereas Medtronic (MDT), Boston Scientific (BSX), and Edwards Lifesciences (EW), which are the other major players in the structural heart device business, saw gains of ~0.83%, ~0.04%, and ~1.2%, respectively.
Edwards Lifesciences (EW) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $15.64 billion.
IRVINE, Calif. , March 6, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...
NEW YORK, March 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Edwards Lifesciences (EW) is a global leader in medical innovation for structural heart disease and critical care monitoring. Edwards Lifesciences’ product pipeline is focused on the repair or replacement of the mitral and tricuspid valves of the heart. Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating, while four analysts have given it a “hold” rating.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio